A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes

The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes in a double-blind randomized placebo-controlled study. A total of 109 patients were randomized to 100 mg (n=37) or 200 mg (n=33) anagliptin twice daily or placebo (n=39). The prima...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine Journal 2015, Vol.62(5), pp.449-462
Hauptverfasser:	Yang, Hae Kyung, Min, Kyung Wan, Park, Sung Woo, Chung, Choon Hee, Park, Kyong Soo, Choi, Sung Hee, Song, Ki-Ho, Kim, Doo-Man, Lee, Moon-Kyu, Sung, Yeon-Ah, Baik, Sei Hyun, Kim, In Joo, Cha, Bong-Soo, Park, Jeong Hyun, Ahn, Yu Bae, Lee, In-Kyu, Yoo, Soon Jib, Kim, Jaetaek, Park, Ie Byung, Park, Tae Sun, Yoon, Kun-Ho
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Blood Glucose - analysis Body Mass Index Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl Peptidase 4 - blood Dipeptidyl-Peptidase IV Inhibitors Double-Blind Method DPP-4 inhibitor Fasting Female Glycated Hemoglobin A - analysis Glycemic control Humans Insulin - blood Male Middle Aged Placebos Proinsulin - blood Pyrimidines - adverse effects Pyrimidines - therapeutic use Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!